Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Stemline Therapeutics
Biotech
Insilico nabs $500M+ biobucks deal for preclinical cancer asset
Menarini's Stemline Therapeutics is paying $12 million upfront for licensing rights to Insilico Medicine’s preclinical cancer candidate.
Gabrielle Masson
Jan 4, 2024 10:00am
Gilead offers $1.76B for option to MacroGenics' bispecific
Oct 17, 2022 11:00am
Stemline licenses RET inhibitor from U.K. cancer group
Mar 11, 2019 9:53am
Stemline admits it learned of patient death before $45M stock offering
Feb 3, 2017 4:38am
